The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria

G. W. Barone, B. J. Gurley, Karl Anderson, B. L. Ketel, S. R. Abul-Ezz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Acute intermittent porphyria results from a deficiency of the porphobilinogen deaminase enzyme of heine biosynthesis and is commonly exacerbated by a wide variety of medications. When referred a patient with acute intermittent porphyria for a renal transplant, only steroids and azathioprine were discovered as safe in patients with acute intermittent porphyria. The administration of many newer immunosuppressive medications, including calcineurin inhibitors, has not been documented in acute intermittent porphyria. Actually, cyclosporine is presently considered contraindicated in acute intermittent porphyria. To determine if calcineurin inhibitors would be tolerated in acute intermittent porphyria, cyclosporine and tacrolimus were administered pretransplant and were documented not to exacerbate acute intermittent porphyria. A successful renal transplant was then performed using tacrolimus. This is the first reported patient with documented acute intermittent porphyria to tolerate safely several of the newer immunosuppressive medications, including tacrolimus, mycophenolate, and rabbit antithymocytic globulin following renal transplantation. This patient's pretransplant evaluation also suggested that cyclosporine may be safe for some patients with acute intermittent porphyria. (C) 2001 the American College of Clinical Pharmacology.

Original languageEnglish
Pages (from-to)113-115
Number of pages3
JournalJournal of Clinical Pharmacology
Volume41
Issue number1
StatePublished - 2001

Fingerprint

Acute Intermittent Porphyria
Immunosuppressive Agents
Tacrolimus
Cyclosporine
Transplants
Kidney
Globulins
Azathioprine
Kidney Transplantation
Steroids
Rabbits

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. / Barone, G. W.; Gurley, B. J.; Anderson, Karl; Ketel, B. L.; Abul-Ezz, S. R.

In: Journal of Clinical Pharmacology, Vol. 41, No. 1, 2001, p. 113-115.

Research output: Contribution to journalArticle

Barone, G. W. ; Gurley, B. J. ; Anderson, Karl ; Ketel, B. L. ; Abul-Ezz, S. R. / The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. In: Journal of Clinical Pharmacology. 2001 ; Vol. 41, No. 1. pp. 113-115.
@article{89195dd200664f988b5a55877fe15ed0,
title = "The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria",
abstract = "Acute intermittent porphyria results from a deficiency of the porphobilinogen deaminase enzyme of heine biosynthesis and is commonly exacerbated by a wide variety of medications. When referred a patient with acute intermittent porphyria for a renal transplant, only steroids and azathioprine were discovered as safe in patients with acute intermittent porphyria. The administration of many newer immunosuppressive medications, including calcineurin inhibitors, has not been documented in acute intermittent porphyria. Actually, cyclosporine is presently considered contraindicated in acute intermittent porphyria. To determine if calcineurin inhibitors would be tolerated in acute intermittent porphyria, cyclosporine and tacrolimus were administered pretransplant and were documented not to exacerbate acute intermittent porphyria. A successful renal transplant was then performed using tacrolimus. This is the first reported patient with documented acute intermittent porphyria to tolerate safely several of the newer immunosuppressive medications, including tacrolimus, mycophenolate, and rabbit antithymocytic globulin following renal transplantation. This patient's pretransplant evaluation also suggested that cyclosporine may be safe for some patients with acute intermittent porphyria. (C) 2001 the American College of Clinical Pharmacology.",
author = "Barone, {G. W.} and Gurley, {B. J.} and Karl Anderson and Ketel, {B. L.} and Abul-Ezz, {S. R.}",
year = "2001",
language = "English",
volume = "41",
pages = "113--115",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria

AU - Barone, G. W.

AU - Gurley, B. J.

AU - Anderson, Karl

AU - Ketel, B. L.

AU - Abul-Ezz, S. R.

PY - 2001

Y1 - 2001

N2 - Acute intermittent porphyria results from a deficiency of the porphobilinogen deaminase enzyme of heine biosynthesis and is commonly exacerbated by a wide variety of medications. When referred a patient with acute intermittent porphyria for a renal transplant, only steroids and azathioprine were discovered as safe in patients with acute intermittent porphyria. The administration of many newer immunosuppressive medications, including calcineurin inhibitors, has not been documented in acute intermittent porphyria. Actually, cyclosporine is presently considered contraindicated in acute intermittent porphyria. To determine if calcineurin inhibitors would be tolerated in acute intermittent porphyria, cyclosporine and tacrolimus were administered pretransplant and were documented not to exacerbate acute intermittent porphyria. A successful renal transplant was then performed using tacrolimus. This is the first reported patient with documented acute intermittent porphyria to tolerate safely several of the newer immunosuppressive medications, including tacrolimus, mycophenolate, and rabbit antithymocytic globulin following renal transplantation. This patient's pretransplant evaluation also suggested that cyclosporine may be safe for some patients with acute intermittent porphyria. (C) 2001 the American College of Clinical Pharmacology.

AB - Acute intermittent porphyria results from a deficiency of the porphobilinogen deaminase enzyme of heine biosynthesis and is commonly exacerbated by a wide variety of medications. When referred a patient with acute intermittent porphyria for a renal transplant, only steroids and azathioprine were discovered as safe in patients with acute intermittent porphyria. The administration of many newer immunosuppressive medications, including calcineurin inhibitors, has not been documented in acute intermittent porphyria. Actually, cyclosporine is presently considered contraindicated in acute intermittent porphyria. To determine if calcineurin inhibitors would be tolerated in acute intermittent porphyria, cyclosporine and tacrolimus were administered pretransplant and were documented not to exacerbate acute intermittent porphyria. A successful renal transplant was then performed using tacrolimus. This is the first reported patient with documented acute intermittent porphyria to tolerate safely several of the newer immunosuppressive medications, including tacrolimus, mycophenolate, and rabbit antithymocytic globulin following renal transplantation. This patient's pretransplant evaluation also suggested that cyclosporine may be safe for some patients with acute intermittent porphyria. (C) 2001 the American College of Clinical Pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=0034751117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034751117&partnerID=8YFLogxK

M3 - Article

C2 - 11144989

AN - SCOPUS:0034751117

VL - 41

SP - 113

EP - 115

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -